Uncategorized
Allergan announces favorable safety, efficacy profile for bimatoprost sustained-release in phase 1/2 trial
Allergan announced positive safety and efficacy results from an interim phase 1/2 clinical trial of a single dose of bimatoprost sustained-release to treat glaucoma, according to a press release.In the 24-month trial, a single dose of non-daily bimatoprost sustained-release (SR), a biodegradable intracameral implant that provides a slow release of bimatoprost, lowered IOP in 92% of patients at 4 months and 71% of patients at 6 months with a favorable efficacy and safety profile, the release said.